Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-163-4 | CAS number: 13676-54-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Acute/short term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- high hazard (no threshold derived)
Acute/short term exposure
- Hazard assessment conclusion:
- high hazard (no threshold derived)
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
Inhalation Systemic effects:
Long-term: A repeated dose toxicity study with administration by the oral route did not record any signs of systemic toxicity caused by the test material. The effects observed in the acute inhalation study seem to be only secondary to local effects in the lung, no systemic toxicity is evident. On this basis it is considered that the substance does not present a hazard for systemic effects following inhalation of the test item.
Short-term: An acute inhalation study indicates a local effect on the lungs, but there were no specific signs of systemic absorption. Nevertheless the substance is classified as acute tox. Cat. 3 (inhalation, dust, LC50 >0.5, <1 mg/L, 4h), and needs hence according toGuidance r.1, part E, table E.3-1, classified as "moderate hazard".
Inhalation Local effects:
BMI was observed to have caused toxicity in an acute inhalation study; the treatment-related deaths were concluded to have been due to localised toxicity in the lungs. It is assumed that this localised toxicity will present a problem for long-term exposure as well as for short-term or acute exposure. The dose levels assessed in the acute toxicity study were sufficient to identify an LD50, but no No Adverse Effect Level could be established because some of the exposed rats died in the lowest dose level; on this basis a quantitative DNEL cannot be derived. BMI is classified as Acute Toxicity Category 3 for inhalation exposure; in accordance with table E3-1 in the "Guidance on information requirements and chemical safety assessment, Part E: Risk Characterisation" Version 2.0 (ECHA, 2012), this classification corresponds to a medium hazard.
Dermal Systemic effects:
Although the phys.-chem. data (logPow = 1.5, water solubility = 0.36 mg/L at 20°C, M
W = 358 Dalton) indicate a certain potential for adsorption, no systemic toxicity due to the substance was apparent in the available oral (acute and repeat dose) or inhalation (acute) studies. So due to the lack of systemic toxicity by inhalation and oral routes, no significant hazard from systemic toxicity following dermal contact is anticipated. According to ECHA's G
uidance on Information Requirements and Chemical Safety Assessment, Part D: Framework for exposure assessment, Version 2.0, August 2016, "if no adverse effects have been observed in studies at the highest recommended concentrations/doses tested, this would normally indicate that no hazard has been identified for the protection target or route/type of effect and therefore no DNEL or PNEC can be derived". In consequence, "no hazard identified" was chosen, which also applies to inhalation toxicity.
Dermal Local effects:
No dermal toxicity data is available for the test item, however a Guinea Pig Maximisation test determined that BMI may cause dermal sensitisation in exposed individuals. The results of this test have resulted in a classification as Skin Sensitiser Category 1A, indicating significant concern for a sensitising effect. No threshold was determined for sensitisation, and so it is not possible to establish a quantitative DNEL for local dermal effects. Due to the concern for a sensitising effect, BMI is considered to present a high hazard for local dermal effects. Although sensitisation typically occurs over a series of exposures (i.e. long-term or chronic exposure) it cannot be confirmed that a sensitisation effect will not occur over a short period of time, and so this hazard is considered applicable to a short-term or acute exposure as well as to long-term.
Hazard for the eyes:
An in-vivo eye irritation study was conducted to assess the effect of instillation of BMI in the eyes of Rabbits. Some slight conjunctival injection and / or chemosis was observed in some animals treated, but this was observed to fully recover by the end of the post-exposure observation period. The severity of the irritation response observed was not sufficient to trigger a classification under the CLP Regulation; on this basis it is concluded that BMI does not present a hazard to the eyes.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
Acute/short term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- high hazard (no threshold derived)
Acute/short term exposure
- Hazard assessment conclusion:
- high hazard (no threshold derived)
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
Inhalation Systemic effects:
Long-term: A repeated dose toxicity study with administration by the oral route did not record any signs of systemic toxicity caused by the test material. The effects observed in the acute inhalation study seem to be only secondary to local effects in the lung, no systemic toxicity is evident. On this basis it is considered that the substance does not present a hazard for systemic effects following inhalation of the test item.
Short-term: An acute inhalation study indicates a local effect on the lungs, but there were no specific signs of systemic absorption. Nevertheless the substance is classified as acute tox. Cat. 3(inhalation, dust, LC50 >0.5, <1 mg/L, 4h), and needs hence according toGuidance r.1, part E, table E.3-1, classified as "moderate hazard".
Inhalation Local effects:
BMI was observed to have caused toxicity in an acute inhalation study; the treatment-related deaths were concluded to have been due to localised toxicity in the lungs. It is assumed that this localised toxicity will present a problem for long-term exposure as well as for short-term or acute exposure. The dose levels assessed in the acute toxicity study were sufficient to identify an LD50, but no No Adverse Effect Level could be established because some of the exposed rats died in the lowest dose level; on this basis a quantitative DNEL cannot be derived. BMI is classified as Acute Toxicity Category 3 for inhalation exposure; in accordance with table E3-1 in the "Guidance on information requirements and chemical safety assessment, Part E: Risk Characterisation" Version 2.0 (ECHA, 2012), this classification corresponds to a medium hazard.
Dermal Systemic effects:
Although the phys.-chem. data (logPow = 1.5,water solubility = 0.36 mg/L at 20°C,M
W = 358 Dalton) indicate a certain potential for adsorption, no systemic toxicity due to the substance was apparent in the available oral (acute and repeat dose) or inhalation (acute) studies. So due to the lack of systemic toxicity by inhalation and oral routes, no significant hazard from systemic toxicity following dermal contact is anticipated. According to ECHA's G
uidance on Information Requirements and Chemical Safety Assessment, Part D: Framework for exposure assessment, Version 2.0, August 2016, "if no adverse effects have been observed in studies at the highest recommended concentrations/doses tested, this would normally indicate that no hazard has been identified for the protection target or route/type of effect and therefore no DNEL or PNEC can be derived". In consequence, "no hazard identified" was chosen, which also applies to inhalation toxicity.
Dermal Local effects:
No dermal toxicity data is available for BMI, however a Guinea Pig Maximisation test determined that BMI may cause dermal sensitisation in exposed individuals. The results of this test have resulted in a classification as Skin Sensitiser Category 1A, indicating significant concern for a sensitising effect. No threshold was determined for sensitisation, and so it is not possible to establish a quantitative DNEL for local dermal effects. Due to the concern for a sensitising effect, BMI is considered to present a high hazard for local dermal effects. Although sensitisation typically occurs over a series of exposures (i.e. long-term or chronic exposure) it cannot be confirmed that a sensitisation effect will not occur over a short period of time, and so this hazard is considered applicable to a short-term or acute exposure as well as to long-term.
Oral effects:
An acute oral toxicity was conducted to assess the toxic potential of BMI when ingested. Even when dosed at the guideline limit dose (2000 mg/kg), no deaths were recorded and no evidence of systemic toxicity were seen either as clinical signs or during a macroscopic pathological examination. A repeat dose toxicity study screening study (incorporating a reproductive toxicity screen) was also conducted using oral dosing; again no deaths were recorded in any of the treated animals, and no signs of systemic or local toxicity were observed either during the in-life phase of the study, or in the post mortem examinations. On the basis of these two studies it is considered that BMI did not cause any localised or systemic toxicity following oral dosing, and therefore does not present any hazard by this route.
Hazard for the eyes:
An in-vivo eye irritation study was conducted to assess the effect of instillation of BMI in the eyes of Rabbits. Some slight conjunctival injection and / or chemosis was observed in some animals treated, but this was observed to fully recover by the end of the post-exposure observation period. The severity of the irritation response observed was not sufficient to trigger a classification under the CLP Regulation; on this basis it is concluded that BMI does not present a hazard to the eyes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.